If You Invested in BORA PHARMACEUTICALS CO LTD (BORAY)
Looking for the current price? See the BORAY quote & overviewWhat $1,000 or $10,000 in BORAY Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Jan 22, 2026 |
|---|---|---|---|---|
| $1,000 | — | — | — | $576 -42% |
| $10,000 | — | — | — | $5,756 -42% |
Based on real historical closing prices, dividend- and split-adjusted, through the latest market close. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for BORAY$1,000 Investment Over Time
BORAY vs S&P 500Year-by-Year Returns
BORAY annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2026 | $4.50 | $2.59 | -42.4% | -42.4% |
About BORA PHARMACEUTICALS CO LTD
Healthcare · OTC Link
Bora Pharmaceuticals Co., Ltd. (BORAY) operates as a pharmaceutical manufacturing company and contract development and manufacturing organization serving commercial drug products and pharmaceutical partners. The company is associated with Taiwan-listed shares under 6472.TW and an OTCQX-traded security under BORAY. Its disclosed operations include global commercial manufacturing, development support, and product supply services for established pharmaceutical products.
Bora’s CDMO business includes manufacturing work for pharmaceutical partners across multiple therapeutic areas. At its Mississauga facility, which Bora purchased from GSK in 2020, the company provides end-to-end manufacturing services for commercial product lines and individual products used in areas that include infectious disease, mental health, dermatology, migraine, and other conditions. The company’s manufacturing network also includes an oral solid dose site in Maple Grove, Minnesota, used within its broader pharmaceutical production infrastructure.
Through Upsher-Smith Laboratories, LLC, a Bora subsidiary, the company also participates in the U.S. prescription pharmaceutical market. Upsher-Smith’s activities include launches of generic and branded prescription products, differentiated dosage forms, and patient and healthcare professional support resources tied to specific medicines. Its disclosed products include KYMBEE (deflazacort) Tablets, indicated for Duchenne muscular dystrophy in patients 5 years of age and older, and Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, a generic version of Ciprodex.
Bora’s business model combines contract manufacturing services for external pharmaceutical companies with product commercialization through its operating subsidiary. Its disclosures emphasize commercial-scale manufacturing, oral solid dose capabilities, product launches, portfolio diversification, and access-support programs connected to prescribed therapies.
Frequently Asked Questions
BORA PHARMACEUTICALS CO LTD investment returns
How much would $1,000 invested in BORA PHARMACEUTICALS CO LTD be worth today?
Limited historical data is available for BORAY. The stock has been trading since 2026-01-22.
Has BORA PHARMACEUTICALS CO LTD outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare BORAY performance over available time periods.
What is BORA PHARMACEUTICALS CO LTD's average annual return?
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
